Abivax shares soar 26% amid renewed takeover chatter
I'm PortAI, I can summarize articles.
Shares of Abivax surged 26% following reports that Eli Lilly is interested in acquiring the French biotech firm for €15 billion ($17.5 billion). This marks Abivax's largest one-day increase since a significant rise in July, attributed to positive Phase III trial results for its drug obefazimod. Brokerage Kepler Cheuvreux noted that Abivax has become an attractive target for mergers and acquisitions after these results.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments